Cross-Reactive Dengue Fully Human Monoclonal Antibodies

Among the arthropod-borne flaviviruses, the four dengue virus serotypes, dengue type 1 virus (DENV-1), dengue type 2 virus (DENV-2), dengue type 3 virus (DENV-3), and dengue type 4 virus (DENV-4) are most important in terms of human morbidity and geographic distribution. Dengue viruses cause dengue outbreaks and major epidemics in most tropical and subtropical areas whereAedes albopictus andAedes aegypti mosquitoes are abundant.A safe and effective vaccine against dengue is currently not available. Passive immunization with monoclonal antibodies from non-human primates or humans represents a possible alternative to vaccines for prevention of illness caused by dengue virus. This invention claims fully human monoclonal antibodies that bind and neutralize dengue type 1, 2, 3 and 4 viruses. It also claims fragments of such antibodies and nucleic acids encoding the antibodies of the invention as well as prophylactic, therapeutic and diagnostic methods employing the antibodies and nucleic acids of the invention.IC: NCINIH Ref. No.: E-273-2011/0TAB No: TAB-2508Advantages: Antibodies are cross-reactive with all four serotypes of dengue.Antibodies are fully human.Applications: Prophylaxis/therapy against dengue serotypes 1, 2, 3, and 4.Dengue diagnostics.Development Status: Pre-clinicalIn vitro dataProvider Technology ID: 2508Updated On: Nov 29, 2017Date Published: Friday, January 11, 2013Provider Classifications: Publications: Pa...

Source: NIH OTT Licensing Opportunities - January 11, 2013 Category: Research Authors: ajoyprabhu3 Source Type: research